🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-522631-34-00
Completed Phase III

J2A-MC-GZPT A Phase 3 Study to Investigate the Efficacy and Safety of Orfor-glipron Once Daily in Participants Who Have Obesity or Overweight and Osteoar-thritis of the Knee: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Pla-cebo-Controlled Trial List of Intervention-Specific Appendices (ISAs): ISA1 (GZT1): A Study to Investigate Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee ISA2 (GZT2): A Study to Investigate Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

2025-522631-34-00 · tracked via the Priya Life Science EU tracker
Sponsor
Eli Lilly & Co.
Sponsor type
Pharmaceutical company
Therapeutic area
Musculoskeletal Diseases
Decision date
29/12/2025
Enrollment target
180
Sites
Germany, Spain

Condition studied

Osteoarthritis

Investigational medicinal product(s)

OrforglipronOrforglipronOrforglipronOrforglipronPlacebo to match LYOrforglipronOrforglipron

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522631-34-00 on CTIS ↗ ← All trials in the EU